Tigo Expands TS4-A Platform with New Add-on UL-system-certified Rapid Shutdown Solution
18.3.2020 16:00:00 EET | Business Wire | Press release
Tigo Energy, Inc.®, pioneer of the smart modular Flex MLPE, today announced a new addition to the add-on TS4 Platform - the TS4-A-S. This add-on safety solution brings the solar market’s only module-level power electronic (MLPE) multivendor UL-system-certified solution for rapid shutdown. Tigo’s safety solution complies with NEC 2014, 2017, and 2020 with more than 100 inverters for residential, commercial & industrial, and utility customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005094/en/
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by Tigo's communication accessories. Production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. Now taking orders for the TS4-A-S worldwide. (Photo: Business Wire)
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by the Tigo Access Point (TAP) and the Cloud Connect Advanced (CCA). DC production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. This TS4-A-S launch accompanies the recently announced TS4-A-M (Monitoring Add-on) launch earlier this month. These units complete Tigo’s transition from the legacy TS4-R retrofit platform to the TS4-A add-on platform with mechanical upgrades, UHD-Core technology, expanded specifications to support PV modules up to 500W. To learn more, join Tigo's free online "Rapid Shutdown featuring the TS4-A-S & NEC 2020" webinar on Thursday, March 26th at 10am PT.
The highlights of the new TS4-A-S (Safety Add-on) with rapid shutdown include:
- Comply with NEC 2014, 2017, 2020 rapid shutdown requirements
- Choose compatibility from more than 100 UL-system-certified inverters
- Choose compatibility from any module up to 500W
- Manual or automatic shutdown in event of AC grid loss
- Automatic email or SMS alerts about faults or operational issues
- Protect PV system assets with full visibility of performance
- Lower O&M costs when identifying specific module problems
- Utilize module manufacturer warranties when tracking module failures
“Only inverters and rapid shutdown devices that have been UL-certified as a system are certified as safe. There’s one multivendor solution for residential C&I – and that’s Tigo,” says Danny Eizips, VP of Hardware Engineering at Tigo. “Others might not meet mandatory safety requirements, and therefore, cannot be trusted as safe when installed together in one PV system. We're working diligently to educate our partners and customers worldwide to know the difference for the safest solar experience.”
Tigo is now taking orders for the TS4-A-S worldwide. The last inventory of legacy TS4-R-S units may be shipped per the discretion of Tigo and Tigo’s distribution partners as the new TS4-A-S shipments are prepared. Both units are fully backward compatible. For price and delivery, consult your preferred solar distributor, call Tigo at +1.408.402.0802, email sales@tigoenergy.com, or visit www.tigoenergy.com.
About Tigo Energy, Inc.
Tigo is a Silicon Valley company founded in 2007 by a team of experienced technologists. Combining a unique systems-level approach with expertise in semiconductors, power electronics, and solar energy, the Tigo team developed the first-generation Smart Module Optimizer technology for the solar industry. Tigo's vision is to leverage integrated and retrofitted Flex MLPE and communications technology to drive the cost of solar electricity down. By partnering with tier 1 module and inverter manufacturers in the industry, Tigo is able to focus on its key innovation with the smartest TS4 modular platform and leverage the broader ecosystem. Tigo has operations in the USA, Europe, Latin America, Japan, China, Australia, and the Middle East. Visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005094/en/
Contact information
Tiffany Douglass
408.402.0802 x 430
marketing@tigoenergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom